Reduced Oestrogen Dosage to Improve the Outcome of Frozen-thawed Embryo Transfer
A Randomized Controlled Trial on Reducing Oestrogen Dosage to Improve the Clinical Outcome of Frozen-thawed Embryo Transfer
Nanjing University
660 participants
Oct 1, 2022
INTERVENTIONAL
Conditions
Summary
This study is a single-center, randomized, controlled prospective study. Those who will recieve hormone replacement therapy-frozen thawed embryo transfer (HRT-FET) are enrolled in the study. To determine the effect of oestrogen dosage reducion on maternal and fetal complications in HRT-FET cycles while maintaining the similar clinical pregnancy outcome in HRT-FET cycles with regular oestrogen dosage.
Eligibility
Inclusion Criteria6
- Female;
- Aged between 20 and 40 years old;
- Frozen thawed embryo transfer is proposed, and the type of transferred embryo is blastocyst (the number of transferred embryos is 1);
- Body mass index (BMI) ≤ 28 kg/m2, ≥ 18.5 kg/m2;
- The total number of transfer cycles was < 3;
- Volunteer to participate in the study and sign the informed consent.
Exclusion Criteria4
- Patients with chromosomal abnormalities;
- Contraindications to hormone replacement therapy;
- Patients with uterine myoma, severe adenomyosis, endometriosis, congenital uterine malformation, endometrial tuberculosis, intrauterine adhesions and other diseases that significantly affect embryo implantation;
- Participating in other clinical studies.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
From the second day of the menstrual cycle, femoston (estradiol tablets) were orally taken 2 mg q.d.. The endometrial thickness and serum oestrogen and progesterone levels were monitored on the 12th to 14th days of the menstrual cycle.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05545592